HER2 status and disparities in luminal breast cancers

National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Holowatyj, Andreana N., Ruterbusch, Julie J., Ratnam, Manohar, Gorski, David H., Cote, Michele L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893351/
https://www.ncbi.nlm.nih.gov/pubmed/27250116
http://dx.doi.org/10.1002/cam4.757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893351/
https://www.ncbi.nlm.nih.gov/pubmed/27250116
http://dx.doi.org/10.1002/cam4.757

Ejemplares similares